Clinical Trial Update: An Observational Study of Type II Diabetics Treated With Dual Therapy With or Without Sitagliptin (Januvia®/Xelevia®, MK-0431-201)

View source ↗

Summary

An observational study comparing outcomes in type 2 diabetes mellitus patients treated with dual therapy including sitagliptin versus without sitagliptin; resul…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Januvia/Xelevia (sitagliptin)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Type 2 Diabetes Mellitus | Status: COMPLETED | Results posted: 2014-12-05